Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Aldesleukin + LV-NY-ESO TCR/sr39TK PBSC + RV-NY-ESO TCR PBMC|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Aldesleukin||Proleukin||IL-2|Interleukin-2|IL2||Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary).|
|LV-NY-ESO TCR/sr39TK PBSC||LV-NYESO TCR/sr39TK PBSC||LV-NYESO TCR/sr39TK PBSC are peripheral blood stem cells that have been engineered to express a NY-ESO-1-specific T-cell receptor and the sr39TK cell suicide gene, which may enhance anti-tumor immune response (PMID: 30409823)|
|RV-NY-ESO TCR PBMC||RV-NYESO TCR PBMC||RV-NY-ESO TCR PBMC are peripheral blood mononuclear cells that have been engineered to express an NY-ESO-1-specific T-cell receptor, which may result in enhanced anti-tumor immunity (PMID: 25038231, PMID: 30409823).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03506802||Phase I||Filgrastim + Plerixafor Lenalidomide Aldesleukin + LV-NY-ESO TCR/sr39TK PBSC + RV-NY-ESO TCR PBMC Melphalan||TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma||Withdrawn||USA||0|
|NCT03240861||Phase I||Busulfan + Fludarabine Aldesleukin + LV-NY-ESO TCR/sr39TK PBSC + RV-NY-ESO TCR PBMC Filgrastim + Plerixafor||Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)||Recruiting||USA||0|